News and Trends 11 Apr 2023 Calida Therapeutics launches to tackle thrombo-inflammatory disorders Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding… April 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Endometrial cancer drug receives breakthrough therapy designation in China …safety of fruquintinib in combination with sintilimab. Entry criteria include those endometrial cancer patients who experienced disease recurrence, disease progression or grade 3 or higher serious adverse events with treatment… July 20, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Apr 2022 Epidarex Backs UK Startup Developing Emerging Anti-Inflammatory Drugs …target. Much of the UK’s biotech innovation is concentrated in the so-called Golden Triangle, encompassing the hubs of Cambridge, Oxford, and London. In 2020, Epidarex Capital raised €112M to tap… April 8, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022 Ilya Pharma enrols first patient in diabetic foot ulcer study …foot ulcers. Additional endpoints include reduction in wound infections, antibiotic saving effects, analyses of the mechanism of action and the impact of ILP100-Topical on significant clinical events, during treatment and… September 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment …the liver, and potential complications such as cirrhosis, liver cancer, and liver failure. Foralumab binds to and inhibits CD3, which prevents cytotoxic and helper T cell activation. Inhibition of their… September 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Podcast 23 Feb 2024 Precision neuromedicine: A new dawn for neurological disorders …co-founder and CSO David Bredt. Neurology received the second-most new drug approvals from the FDA in 2023 among all disease areas. The year ended with two multi-billion M&A events: BMS’s… February 23, 2024 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 A Breath of Fresh Air for Biotechs Working on Cystic Fibrosis Therapies? …Cystic fibrosis is a severe genetic disease affecting the lungs, for which there is currently no cure. It is caused by a malfunctioning chloride channel, CFTR, which prevents the secretion… December 14, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease …however the power to detect this was limited by the number of events observed. Reduction in the risk of these endpoints is consistent with the totality of the evidence from other… November 4, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2023 Certa scleroderma study shows improvement in more than 60% of patients …demonstrated statistically significant improvements over 12 weeks of treatment when compared to placebo for pain, breathing problems, finger ulcers and overall disease activity. No adverse events Global physician assessments of… February 7, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Newron reports ‘striking’ schizophrenia study results …to the current antipsychotic medication continued to be well tolerated, only two patients discontinued for adverse events (flu-like symptoms and headache) after one year of treatment. Better than expected results… February 16, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 New biotech company aims to bridge gap between stem cell research and athletic injuries Andrews Medicine of Pensacola, Florida, and Celltex Therapeutics Corporation of Houston, Texas, are to form a new biotechnology company to bridge the divide between stem cell research and the current… October 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 May 2019 First Potential Gene Therapy for Hemophilia B Restores Blood Clotting in Phase II A gene therapy developed by the Dutch biotech uniQure increased the activity of a blood clotting protein enough to stop bleeds in patients with the blood disorder hemophilia B. Hemophilia… May 14, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email